VEGFA and neoplasm: Pre-clinical studies have demonstrated tumour growth and angiogenesis inhibition using Ang2 blocking reagents, especially, when combined with VEGF-based anti-angiogenic therapies [12,20–23] as well as inhibition of lymph node and distant metastasis [21,24,25].